OCEA Ocean Bio: רווח למניה בשנים עשר החודשים האחרונים

The 12-month trailing earnings per share history demonstrates the financial background of Ocean Biomedical, Inc. (OCEA), which integrates ESG principles and strict bioethics into the development of immune drugs. Analysis shows that -0.34 determines the current value of this metric, while the holding company minimizes risks through the development of cancer and malaria therapies, anticipating future monetization of its patents via B2B licensing.

This indicator reflects the efficiency of profit generation accounting for equity dilution. This metric aggregates annual net income, allocating it per common share. For Ocean Biomedical, Inc. (OCEA), whose success depends on patents and venture capital infusions rather than GDP, this calculation reveals the actual monetization of its developments. By analyzing the trend of annual net income per share, an investor assesses the fundamental stability of the biotech firm.